A carefully designed proof-of-principle study demonstrated that CAR-T EVs with EGFR and HER-2 specific CAR efficiently and specifically kill HER2+ and EGFR+ cancer cells in mouse xenograft models, without impacting cells that do not express those molecules [143]. The gene discussed is ERBB2; the disease is cancer.